Kelun-Biotech Highlights Major NSCLC Data at ASCO 2026
CHENGDU, China, 21 May 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that two registrational studies involving its lead oncology...
Mabwell
Advertisement
Mabwell Showcases Strong 9MW2821 Bladder Cancer Data at ASCO 2026
SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...
Mabwell Expands MAIWEIJIAN Approval for Cancer Bone Complications in China
SHANGHAI, China, May 20, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has approved the supplemental application...
Halozyme and GSK Partner on Next-Gen ADC Cancer Therapies
SAN DIEGO, May 7, 2026 Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to...
Mabwell Wins FDA IND Clearance for 9MW5211 in IBD
SHANGHAI, China – May 8, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that...
Advertisements
Mabwell 9MW2821 Advances to Phase III in TNBC Trial
SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...
Mabwell Advances SST001 PET Tracer to Phase I Trial
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
Advertisement
